Latest Filings

Issuer Activity

Overview :: ABIOMED, Inc. (OQ:ABMD) [?]
Business Focus: Advanced Medical Equipment & Technology Share on StockTwits
Recent Price for ABMD
USD 24.64 +0.16 (+0.65%)
NSQ Delayed 15 minutes
Apr 17 Close
1-Day High 52-Week High P/E 1-Day Volume Mkt Cap ($Mil)
24.86 30.77 136.88 235,776 981.12
1-Day Low 52-Week Low Yield Avg. Volume  
24.25 17.00 0.0% 601,176  
Log in or sign up for a free account to add this stock to your watch list. During beta also get free PDF company reports for US stocks.

Latest 10 SEC filings (by transaction date) for ABMD within the last 6 months [?]
Amended Filing      Footnote and/or Remark
As of 12:17am ET April 19th, 2014
Filing
Date
Transaction
Date
Insider Name Ownership
Type
Securities Nature of transaction # or value acquired or disposed of Price
Apr 2/14 Mar 31/14 Bolt William J Direct Ownership Common Stock, $.01 par A - Grant, award or other under Rule 16b-3(d) 295 $16.27
Apr 2/14 Mar 31/14 Minogue Michael R Direct Ownership Common Stock $.01 par value A - Grant, award or other under Rule 16b-3(d) 768 $16.27
Apr 2/14 Mar 31/14 Sutter Martin P Direct Ownership Common Stock, $0.01 par value A - Grant, award or other under Rule 16b-3(d) 625  
Mar 6/14 Mar 4/14 Austen W Gerald Direct Ownership Common Stock, $.01 par value A - Grant, award or other under Rule 16b-3(d) 7,401  
Feb 18/14 Feb 13/14 Austen W Gerald Direct Ownership Stock Option (right to buy) M - Exercise or conversion exempt under rule 16b-3 -8,000  
Feb 18/14 Feb 13/14 Austen W Gerald Indirect Ownership Common Stock, $.01 par value S - Open market or private sale -8,000 $28.20
Feb 18/14 Feb 13/14 Austen W Gerald Indirect Ownership Common Stock, $.01 par value M - Exercise or conversion exempt under rule 16b-3 8,000 $13.21
Feb 18/14 Feb 13/14 Howley Michael G Direct Ownership Stock Option (right to buy) M - Exercise or conversion exempt under rule 16b-3 -15,000  
Feb 18/14 Feb 13/14 Howley Michael G Direct Ownership Common Stock, $.01 par value S - Open market or private sale -15,000 $28.10
Feb 18/14 Feb 13/14 Howley Michael G Direct Ownership Common Stock, $.01 par value M - Exercise or conversion exempt under rule 16b-3 15,000 $5.86
Sign up for a free account or login above to see all SEC filings within the past 6 months. During our beta offer, get free access to company PDF reports.
Latest 10 SEC filings (by filing date) for ABMD within the last 6 months [?]
Amended Filing      Footnote and/or Remark
As of 12:17am ET April 19th, 2014
Filing
Date
Transaction
Date
Insider Name Ownership
Type
Securities Nature of transaction # or value acquired or disposed of Price
Apr 2/14 Mar 31/14 Bolt William J Direct Ownership Common Stock, $.01 par A - Grant, award or other under Rule 16b-3(d) 295 $16.27
Apr 2/14 Mar 31/14 Minogue Michael R Direct Ownership Common Stock $.01 par value A - Grant, award or other under Rule 16b-3(d) 768 $16.27
Apr 2/14 Mar 31/14 Sutter Martin P Direct Ownership Common Stock, $0.01 par value A - Grant, award or other under Rule 16b-3(d) 625  
Mar 6/14 Mar 4/14 Austen W Gerald Direct Ownership Common Stock, $.01 par value A - Grant, award or other under Rule 16b-3(d) 7,401  
Feb 18/14 Feb 13/14 Austen W Gerald Direct Ownership Stock Option (right to buy) M - Exercise or conversion exempt under rule 16b-3 -8,000  
Feb 18/14 Feb 13/14 Austen W Gerald Indirect Ownership Common Stock, $.01 par value S - Open market or private sale -8,000 $28.20
Feb 18/14 Feb 13/14 Austen W Gerald Indirect Ownership Common Stock, $.01 par value M - Exercise or conversion exempt under rule 16b-3 8,000 $13.21
Feb 18/14 Feb 13/14 Howley Michael G Direct Ownership Stock Option (right to buy) M - Exercise or conversion exempt under rule 16b-3 -15,000  
Feb 18/14 Feb 13/14 Howley Michael G Direct Ownership Common Stock, $.01 par value S - Open market or private sale -15,000 $28.10
Feb 18/14 Feb 13/14 Howley Michael G Direct Ownership Common Stock, $.01 par value M - Exercise or conversion exempt under rule 16b-3 15,000 $5.86
Sign up for a free account or login above to see all SEC filings within the past 6 months. During our beta offer, get free access to company PDF reports.
Sign up for a free account or login above to see the past 6 months of filings sorted by insider. During our beta offer, get free access to company PDF reports.
Sector:  Healthcare Industry:  Advanced Medical Equipment & Technology
 
See Regulatory Filings on SEC
Key People
Michael R. Minogue
Chairman of the Board, President, Chief Executive Officer
Robert L. Bowen
Chief Financial Officer, Vice President, Treasurer
David M. Weber
Chief Operating Officer
William J. Bolt
Senior Vice President - Global Product Operations
Michael G. Howley
Vice President, General Manager - Global Sales and Marketing
Andrew J Greenfield
Vice President - Healthcare Solutions
Company Contact
Address: 22 Cherry Hill Drive
DANVERS MA 01923
Tel: 1-978-6461812
Website: www.abiomed.com
IR: investors.abiomed.com
Business Overview
ABIOMED, Inc. is a provider of mechanical circulatory support devices and offers a continuum of care to heart failure patients. The Company develops, manufacture and market products that is designed to enable the heart to rest, heal and recover by improving blood flow and/or performing the pumping function of the heart. The Company's products are used in the cardiac catheterization lab (cath lab) by interventional cardiologists and in the heart surgery suite by heart surgeons for patients who are in need of hemodynamic support prophylactically or emergently before, during or after angioplasty or heart surgery procedures. In April 2014, the Company acquired exclusive license from collaboration partner Opsens Inc.
Financial Overview
For the nine months ended 31 December 2013, ABIOMED, Inc. revenues increased 16% to $133.2M. Net income decreased 67% to $3.7M. Revenues reflect an increase in demand for the Company's products and services due to favorable market conditions. Net income was offset by Other income (expense), net) decrease of 98% to $5K (income). Basic Earnings per Share excluding Extraordinary Items decreased from $0.29 to $0.09.
Employees: 467 as of Mar 31, 2013
Reporting Currency: U.S. Dollars
Enterprise value: $901.54M as of Dec 31, 2013
Annual revenue (TTM): $176.88M as of Dec 31, 2013
EBITDA (TTM): $11.32M as of Dec 31, 2013
Net annual income (TTM): $7.47M as of Dec 31, 2013
Free cash flow (TTM): $18.06M as of Dec 31, 2013
Net Debt Last Fiscal Year: N/A
Shares outstanding: 39,818,029 as of Jan 31, 2014
Index Membership: S&P 600 Small Cap
TTM: Trailing Twelve Months
EBITDA: Earnings Before Interest, Taxes, Depreciation, & Amortization
Competitors with Recent Insider Filings
Illumina (OQ:ILMN)
Thermo Fisher Scientific (N:TMO)
Waters (N:WAT)